Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced that it has entered into a five-year term loan facility with funds managed by Pharmakon Advisors, LP.

The non-dilutive financing consists of:

  • $75 million tranche funded at closing, a portion of which was used to retire Kestra’s existing $45 million term loan and pay fees and expenses.
  • $25 million tranche available at Kestra’s option through July 2027.
  • $50 million tranche available at Kestra’s option through June 2028, subject to generating $150 million of trailing 12-months revenue.
  • $50 million uncommitted tranche available for acquisitions at Kestra’s option, subject to Pharmakon’s consent.